Nov 2, 2023
Walvax presents safety and non-inferior immunogenicity results of its MPV ACYW135 compared with Menactra® at Leading Scientific Conferences
Learn More
Nov 2, 2023
Walvax publishes data from the Phase 3b trial of Walrinvax™ administered in a reduced dosing regimen among adolescent girls in Vaccine
Learn More
Oct 8, 2023
Weuphoria Launching Ceremony Successfully Held in Thailand
Learn More
Sep 27, 2023
Walvax Participated in the 24th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN) in Cape Town, South Africa
Learn More
Sep 26, 2023
Walvax and RNAcure Announce Safety, Immunogenicity and Efficacy Data from Phase 3b Clinical Study of RQ3013 (SARS-CoV-2 Variants mRNA Vaccine) Published in eClinicalMedicine
Learn More
Jul 5, 2023
Walvax publishes safety and non-inferior immunogenicity results of its MPV ACYW135 compared with Menactra® in Human Vaccines & Immunotherapeutics
Learn More
May 31, 2023
Walvax publishes data on safety, immunogenicity and immune persistence from the Phase 2 trial of its bivalent HPV vaccine Walrinvax™ in Human Vaccines & Immunotherapeutics
Learn More
May 19, 2023
Walvax’s PCV13-TT Receives Endorsement from the Pediatric Infectious Disease Society of Thailand
Learn More
Apr 14, 2023
Walvax publishes safety and preliminary immunogenicity results from the Phase 1 trial of its bivalent HPV vaccine Walrinvax™ in journal Vaccine
Learn More
Media Contact
Media Team
media@walvax.com
